Natera, Inc.

NASDAQ:NTRA

Medical - Diagnostics & Research

Healthcare
$289.50 +0.98%

+$2.23 today

Market cap
$41.98B
Beta
1.54
P/E (TTM)
-143.0
EPS (TTM)
-$1.60
52W Low $131.81High $256.36

Volume 1.96M

Average 1.41M

NTRA Sales of Investments

Cash received from selling or redeeming investments.

Natera, Inc.NASDAQ: NTRA

Sales of Investments · Q2 FY2026 · quarter ended Jun 2026

Sales of investments outflow shrinks to $0

Q2 FY2026 sales of investments was $0, compared with $2M a year earlier. Trailing-twelve-month sales of investments was $16M. Over 3 fiscal years it compounded at -63.3% a year.

Context

  • Sales of investments amounted to 1.0% of revenue in FY2025, down 19.0 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly sales of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of $4M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$23M-93.2% YoY
LTMJun 2026
$16M-87.2% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-93.2%——
3-year CAGR-63.3%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
23M USD
Year-over-year change
-93.2%
4-year CAGR
-57.7%

Sales of Investments vs competitors

How NTRA compares with its peers on the latest reported figures

  • NTRA's LTM Jun 2026 sales of investments of $16M is the 6th largest of the 8 companies compared; the peer median is $58.07M.
  • Its year-over-year change of -87.2% is the 5th highest of 6, against a peer median of -22.1%.
  • Sales of investments amounts to 0.6% of revenue for NTRA, versus a peer median of 27.3%.
NTRA Competitors Peer median
Sales of Investments for NTRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FLGTFulgent Genetics, Inc.LTM Mar 2026$260.27M -22.1%-17.3%81.2%
PSNLPersonalis, Inc.LTM Mar 2026$171.96M +77.7%-5.0%266.5%
VCYTVeracyte, Inc.LTM Jun 2026$153.19M —+129.5%27.3%
SERASera Prognostics, Inc.LTM Mar 2026$58.07M +18.1%+3.2%101877.2%
WGSGeneDx Holdings Corp.LTM Jun 2026$42.07M -28.7%—9.3%
NTRANatera, Inc.LTM Jun 2026$16M -87.2%-63.3%0.6%
BLLNBillionToOne, Inc.LTM Jun 2026$0 ——0.0%
MYGNMyriad Genetics, Inc.LTM Mar 2026$0 -100.0%—0.0%
Peer median (excluding NTRA) $58.07M-22.1%-0.9%27.3%

Competitors are the stored peer set for NTRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(471.72M)(547.8M)(434.8M)(190.43M)(208.16M)
Depreciation & Amortization11.25M16.7M24.1M30.97M43.48M
Deferred Income Tax00000
Stock-Based Compensation115.22M152.38M191.81M274.43M354.4M
Change in Working Capital(45.6M)(83.15M)(47.95M)2.14M10.05M
Accounts Receivables(43.51M)(122.31M)(33.9M)(35.88M)20.75M
Inventory(6.88M)(8.5M)(5.35M)(3.99M)(20.87M)
Accounts Payables19.22M5.46M(15.46M)13.21M753K
Other Working Capital(14.44M)42.2M6.76M28.79M9.41M
Other Non-Cash Items55.61M30.36M19.89M18.55M15.53M
Operating Cash Flow(335.24M)(431.5M)(246.96M)135.66M215.3M
Capital Expenditures(41.03M)(47.7M)(39.2M)(66.42M)(106.19M)
Acquisitions (Net)0000(16.02M)
Purchases of Investments(876.1M)(86.95M)(98.3M)(124.68M)0
Sales of Investments720.49M464.98M306M339.22M23M
Other Investing Activities(8.56M)00(10.5M)0
Investing Cash Flow(205.19M)330.34M168.5M137.62M(132.21M)
Debt Repayment030M0(82K)0
Common Stock Issued576.19M452.64M254.46M30.29M47.46M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow576.19M482.64M254.46M30.2M47.46M
Effect of Forex Changes00000
Net Change in Cash35.76M381.48M176M303.49M130.55M
Free Cash Flow(376.27M)(479.2M)(286.15M)69.24M109.11M

Natera, Inc.

NASDAQ:NTRA

Intrinsic Alpha fair value

Locked

Current Price

$289.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.